Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 11/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5723776 | 0.96 | ENPP2 (0.41) | ENPP2ACKR3DRD4HSP90AA1HSP90AB1 | |
| SCHEMBL5724411 | 0.96 | ENPP2 (0.41) | ENPP2ACKR3DRD4HSP90AA1HSP90AB1 | |
| SCHEMBL5723837 | 0.93 | CHRM4 (0.37) | ENPP2ACKR3MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5724248 | 0.90 | ENPP2 (0.45) | ENPP2ACKR3HTTMAPTDRD4 | |
| SCHEMBL5724325 | 0.88 | MAPT (0.41) | HTTMAPTSMN1; SMN2ALDH1A1DPP8 | |
| SCHEMBL5724052 | 0.87 | ENPP2 (0.42) | ENPP2ACKR3HTTMAPTDRD4 | |
| SCHEMBL5723786 | 0.86 | ENPP2 (0.43) | ENPP2ACKR3DRD4HSP90AA1HSP90AB1 | |
| SCHEMBL5724146 | 0.86 | ENPP2 (0.43) | ENPP2ACKR3DRD4HSP90AA1HSP90AB1 | |
| SCHEMBL5723581 | 0.84 | DPP8 (0.43) | MAPTALDH1A1DPP8DPP9 | |
| SCHEMBL5723860 | 0.84 | RAB9A (0.47) | HTTMAPTSMN1; SMN2ALDH1A1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | ENPP2 2178/4885ACKR3 4262/4885HTT 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.